Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Britney Haymond

Physician Assistant Flower Mound, TX Physician Assistant

NPI 1396224416 CMS profile 10852376

2620 Long Prairie Rd Ste 100, Flower Mound, TX 75022

Open in the dashboard

General payments

$16,048

907 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Britney Haymond of Flower Mound, TX is reported in the CMS Open Payments database as having received $16,048 across 907 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,624 206
2024 General $3,418 184
2023 General $3,492 199
2022 General $2,830 174
2021 General $2,684 144

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Britney Haymond
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Britney Haymond were reported at $3,624. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Britney Haymond Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,684 $132 $37–$438 $132
2022 $2,830 $155 $48–$522 $149
2023 $3,492 $167 $52–$557 $160
2024 $3,418 $178 $55–$600 $164
2025 $3,624 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,587 136 payments
  2. ITI, Inc. $1,916 126 payments
  3. Supernus Pharmaceuticals, Inc. $1,455 70 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $1,351 76 payments
  5. Otsuka America Pharmaceutical, Inc. $1,258 84 payments
  6. Corium, Inc. $1,172 65 payments
  7. Lundbeck LLC $1,044 60 payments
  8. Teva Pharmaceuticals USA, Inc. $1,011 36 payments
  9. Sunovion Pharmaceuticals Inc. $649 43 payments
  10. Neos Therapeutics, LP $646 41 payments
  11. Other $2,959 170 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,807 902 payments
  2. Education $241 5 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $1,912 104 payments
  2. TRINTELLIX $1,351 76 payments
  3. CAPLYTA $1,332 90 payments
  4. Azstarys $1,172 65 payments
  5. REXULTI Psychiatry $1,072 70 payments
  6. Qelbree $964 35 payments
  7. REXULTI Psychiatry $934 51 payments
  8. AUSTEDO $830 34 payments
  9. VRAYLAR Neuroscience $676 32 payments
  10. LATUDA $649 43 payments
  11. Other $6,229 377 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

42

Median for Physician Assistant: 241

Drug cost

$8,747

Median for Physician Assistant: $4,110

Branded share of claims

42.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trintellix Vortioxetine Hydrobromide Brand 18 $8,536
Olanzapine Generic 13 $125
Promethazine Hcl Generic 11 $86

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $714
$714 — —
REXULTI
  • Lundbeck LLC $272
  • Otsuka America Pharmaceutical, Inc. $216
$488 — —
VRAYLAR
  • AbbVie, Inc. $467
$467 — —
Azstarys
  • Corium, Inc. $344
$344 — —
CAPLYTA
  • ITI, Inc. $342
$342 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

907 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record